Going-concern and liquidity dependence
The company has recurring losses and needs external financing to continue operations.
- Scope
- R&D, regulatory, and commercial programs
- Materiality
- high
Quantum Cyber N.V.
Quantum Cyber N.V. is a U.S.-based life sciences company that has developed in-vitro diagnostic tests for early cancer detection, including colorectal and pancreatic screening products. The company has also held intellectual property and related assets tied to these diagnostic programs and has operated through subsidiaries and commercialization partners in Europe.
−2 890,3 %
72,6 %
−3 018,3 %
−39,9 %
0.50
0.44
| % | |
|---|---|
| Colorectal cancer screening | 55% Stool-based and related colorectal cancer detection products and assets. |
| Pancreatic cancer screening | 25% Blood-based and stool-based pancreatic cancer detection development programs. |
| Intellectual property and asset sales | 15% Sales of diagnostic IP, product assets, and related equipment or lease obligations. |
| Consumables and instrumentation | 5% Consumables and customer-located instruments used with diagnostic testing. |
The company’s customers have included laboratory partners, diagnostic distributors, and other commercial counterparties...
- Laboratory partnersprimary
Buy ColoAlert and related consumables for use in screening workflows and last-time purchases.
- Diagnostic commercialization partnersprimary
Distribute or support cancer screening products in European markets.
- IP and asset buyerssecondary
Acquire product lines, intellectual property, and related equipment for strategic use.
- Clinical testing end userssecondary
Use the company’s diagnostic products through partner channels for early cancer detection.
- Future strategic collaboratorsemerging
Potential partners for development and commercialization of pancreatic screening programs.
The company has historically operated in Europe through its German subsidiary and marketed ColoAlert in European...
- •European markets were the main commercial area for ColoAlert
- •Germany housed the operating subsidiary and development activity
- •United States was a target market for future colorectal launch
- •Italy appeared as the buyer location in a 2026 IP sale
- •Cross-border operations increase regulatory and partner complexity
The company’s strategy has centered on narrowing its focus to pancreatic cancer screening while monetizing legacy...
01
Advance pancreatic cancer screening commercializationmedium-term
This is the remaining core life sciences program after the colorectal exit.
02
Monetize non-core diagnostic assetsshort-term
Asset sales can convert legacy IP into cash and simplify the portfolio.
03
Secure external financingshort-term
Development-stage diagnostics require ongoing capital for R&D and operations.
The company faces going-concern and financing risk because it has recurring losses and depends on external capital to...
Commercialization and regulatory risk
Diagnostic products require validation, approvals, and market adoption before scaling.
- Scope
- Pancreatic screening and any future launches
- Materiality
- high
Portfolio transition risk
Exiting colorectal cancer screening can reduce near-term revenue and operational continuity.
- Scope
- Legacy product lines and partner relationships
- Materiality
- high
Partner concentration and asset monetization risk
Revenue and cash generation depend on a limited set of lab partners and buyers.
- Scope
- ColoAlert sales and IP transactions
- Materiality
- medium
Revenue recognition for diagnostic product sales
Reported revenue and gross margin
Discontinued operations
Operating income and revenue comparability
Impairment of fixed and intangible assets
Operating expenses and asset values
Stock-based compensation
General and administrative expense
: 16/06/2026